FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
Top Cited Papers
Open Access
- 24 April 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 97 (6), 683-694
- https://doi.org/10.1007/s12185-013-1334-8
Abstract
No abstract availableKeywords
This publication has 105 references indexed in Scilit:
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature, 2012
- Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single InstitutionTransplantation and Cellular Therapy, 2011
- Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitorBritish Journal of Cancer, 2010
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseBlood, 2009
- BH3 mimetics to improve cancer therapy; mechanisms and examplesDrug Resistance Updates, 2007
- Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatmentProceedings of the National Academy of Sciences of the United States of America, 2007
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsBlood, 2006
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004